ArticleBMC medicine2023

Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas.

Xiaojie Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.